(ingredient cost = €3243). Potential savings if the cheapest generic omeprazole equivalent were dispensed (instead of proprietary omeprazole) would be approximately 6.2% of the total hospital expenditure on PPIs for the period examined. When follow-up prescriptions in the community were examined approximately 60% of patients did not receive further PPI medication. Of those who continued to receive a prescription for a PPI, approximately 30% remained on the PPI prescribed in hospital. CONCLUSIONS: Considering that generic omeprazole has the same therapeutic indications as proprietary omeprazole, there exists a case for more generic PPI utilisation in Irish hospitals. However, the fact that lansoprazole is priced comparably to generic omeprazole is encouraging. Regarding follow-up PPI prescribing in the community, it appears that where follow-up prescriptions are issued, GPs are more likely to reproduce the hospital prescription, rather than switch to an alternative PPI.
OBJECTIVES:
Medicines waste, with both public health and economic impact, has been identified as a problem within the Portuguese National Health Service (PNHS). This provided the rational to identify the extent of medicines wastage due to inadequacy of medicines pack sizes to the proposed treatments length and to further estimate non-used medicines due to patients' nonadherence, regardless of packs inadequacy. METHODS: A pharmacy-based prospective two phase study was carried out. New medication users were invited to participate. Prescribed pack sizes were scrutinized to evaluate the extent in which they matched treatment lengths. First-phase study enrollees were further invited to participate in a telephone interview for pill counting at the end of the prescribed treatment period (second phase of the study). RESULTS: From September 2005 to March 2006, 1501 patients were included in the study first phase (mean age 50.1, 68.6% females). A total of 2098 medicines were dispensed to these patients. The cost of wastage associated with medicines pack sizes was on average 1.75 € [95% CI: 1.51 €-2.00 €] with 58.5% being charged to the PNHS. This cost was higher than 4.00 € for anti-inflammatory and antirheumatic products, drugs for acid related disorders, corticosteroids for systemic use, drugs for obstructive airway diseases, and antiprotozoals. However the wastage cost represented more than 25% of total expenditure only for anti-inflammatory and antirheumatic products (28.8%) and corticosteroids for systemic use (41.1%). Follow-up data was already collected for 1298 patients, so results from wastage due to patients' non-adherence, regardless of packs inadequacy, will also be presented. CON-CLUSIONS: The wastage associated with the size of medicines packs prescribed is significant in particular for some therapeutic groups. Total wastage is expected to be higher taking into consideration patients' non-compliance.
PHP13 BENEFIT INCIDENCE ANALYSIS BEFORE AND AFTER UNIVERSAL COVERAGE IN THAILAND
Prakongsai P, Tangcharoensathien V International Health Policy Program-Thailand, Nonthaburi, Thailand OBJECTIVES: To investigate changes in the distribution of government health resources towards different socio-economic groups of Thais after implementation of the policy on universal coverage (UC). Effectiveness of the UC policy in improving equity in access to health services and distribution of government health resources were also assessed. METHODS: Four main steps of benefit incidence analysis were employed in order to analyze the distribution of the net government health subsidies. The analysis of benefit incidence between different approaches: using household income and asset index to classify individual socio-economic status; and using aggregated and regional government unit subsidies. There was not a significant difference in the distribution of government health subsidies when income and asset index were used as means testing, or using aggregated unit subsidies, compared to regional variations. CONCLUSIONS: The UC policy
